Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $1.7 million.

  • Immuneering's Share-based Compensation rose 5.13% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.5 million, marking a year-over-year increase of 13.52%. This contributed to the annual value of $6.5 million for FY2024, which is 13.52% up from last year.
  • Immuneering's Share-based Compensation amounted to $1.7 million in Q4 2024, which was up 5.16% from $1.6 million recorded in Q3 2024.
  • In the past 5 years, Immuneering's Share-based Compensation ranged from a high of $1.7 million in Q4 2024 and a low of $182,225 during Q1 2021.
  • Its 3-year average for Share-based Compensation is $1.4 million, with a median of $1.4 million in 2023.
  • Data for Immuneering's Share-based Compensation shows a peak YoY surged of 392.61% (in 2022) over the last 5 years.
  • Immuneering's Share-based Compensation (Quarterly) stood at $216,607 in 2020, then soared by 192.04% to $632,583 in 2021, then soared by 65.70% to $1.0 million in 2022, then spiked by 56.52% to $1.6 million in 2023, then grew by 5.13% to $1.7 million in 2024.
  • Its Share-based Compensation was $1.7 million in Q4 2024, compared to $1.6 million in Q3 2024 and $1.7 million in Q2 2024.